Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 296

1.

Bilateral pleural effusion as an initial manifestation of multiple myeloma: A case report and literature review.

Jiang AG, Yang YT, Gao XY, Lu HY.

Exp Ther Med. 2015 Mar;9(3):1040-1042. Epub 2015 Jan 15.

PMID:
25667674
[PubMed]
Free PMC Article
2.

Bortezomib induces AMPK-dependent autophagosome formation uncoupled from apoptosis in drug resistant cells.

Jaganathan S, Malek E, Vallabhapurapu S, Vallabhapurapu S, Driscoll JJ.

Oncotarget. 2014 Dec 15;5(23):12358-70.

PMID:
25481044
[PubMed - in process]
Free PMC Article
3.

Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3.

Wang W, Zhang Y, Lv M, Feng J, Peng H, Geng J, Lin Z, Zhou T, Li X, Shen B, Ma Y, Qiao C.

J Ovarian Res. 2014 Nov 26;7(1):103. [Epub ahead of print]

PMID:
25424625
[PubMed - as supplied by publisher]
Free PMC Article
4.

Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy.

Deshaies RJ.

BMC Biol. 2014 Nov 11;12:94. doi: 10.1186/s12915-014-0094-0.

PMID:
25385277
[PubMed - in process]
Free PMC Article
5.

An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma.

Offidani M, Corvatta L, Caraffa P, Gentili S, Maracci L, Leoni P.

Onco Targets Ther. 2014 Sep 29;7:1793-800. doi: 10.2147/OTT.S49187. eCollection 2014. Review.

PMID:
25302026
[PubMed]
Free PMC Article
6.

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma.

Dimopoulos MA, Orlowski RZ, Facon T, Sonneveld P, Anderson KC, Beksac M, Benboubker L, Roddie H, Potamianou A, Couturier C, Feng H, Ataman O, van de Velde H, Richardson PG.

Haematologica. 2015 Jan;100(1):100-6. doi: 10.3324/haematol.2014.112037. Epub 2014 Sep 26.

PMID:
25261096
[PubMed - in process]
Free PMC Article
7.

Late recurrence of light chain deposition disease after kidney transplantation treated with bortezomib: a case report.

Moiz A, Javed T, Garces J, Staffeld-Coit C, Paueksakon P.

Ochsner J. 2014 Fall;14(3):445-9.

PMID:
25249814
[PubMed]
Free PMC Article
8.

Advances in multiple myeloma therapy during two past decades.

Spicka I.

Comput Struct Biotechnol J. 2014 Jun 11;10(16):38-40. doi: 10.1016/j.csbj.2014.05.005. eCollection 2014 Jun. Review.

PMID:
25210597
[PubMed]
Free PMC Article
9.

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis.

Reece DE, Hegenbart U, Sanchorawala V, Merlini G, Palladini G, Bladé J, Fermand JP, Hassoun H, Heffner L, Kukreti V, Vescio RA, Pei L, Enny C, Esseltine DL, van de Velde H, Cakana A, Comenzo RL.

Blood. 2014 Oct 16;124(16):2498-506. doi: 10.1182/blood-2014-04-568329. Epub 2014 Sep 8.

PMID:
25202139
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The future of proteasome inhibitors in relapsed/refractory multiple myeloma.

Orlowski RZ.

Oncology (Williston Park). 2011 Nov 15;25 Suppl 2:56-64. Review.

PMID:
25188482
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy.

Hultcrantz M, Svensson T, Derolf ÅR, Kristinsson SY, Lindqvist EK, Ekbom A, Granath F, Björkholm M.

Cancer Med. 2015 Jan;4(1):147-54. doi: 10.1002/cam4.316. Epub 2014 Aug 26.

PMID:
25155101
[PubMed - in process]
Free PMC Article
13.

Bortezomib in multiple myeloma: systematic review and clinical considerations.

Kouroukis TC, Baldassarre FG, Haynes AE, Imrie K, Reece DE, Cheung MC.

Curr Oncol. 2014 Aug;21(4):e573-603. doi: 10.3747/co.21.1798. Review.

PMID:
25089109
[PubMed]
Free PMC Article
14.

The challenge of cross-trial comparisons using limited data.

Laubach JP, Faber EA Jr, Voorhees P, Moslehi J, Varga C, Niculescu L, Anderson KC, Richardson PG.

Haematologica. 2014 Aug;99(8):e145-6. doi: 10.3324/haematol.2013.103135. No abstract available.

PMID:
25082787
[PubMed - in process]
Free PMC Article
15.

The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells.

Hamouda MA, Belhacene N, Puissant A, Colosetti P, Robert G, Jacquel A, Mari B, Auberger P, Luciano F.

Oncotarget. 2014 Aug 15;5(15):6252-66.

PMID:
25051369
[PubMed - in process]
Free PMC Article
16.

The positive effects of one-hour intravenous administration of bortezomib on peripheral neuropathy in multiple myeloma patients.

Jung JY, Kim HY, Han B, Choi DR, Zang DY, Kim HJ.

Biomed Res Int. 2014;2014:237698. doi: 10.1155/2014/237698. Epub 2014 Jun 4.

PMID:
24995276
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Bortezomib and dexamethasone for multiple myeloma: higher AST and LDH levels associated with a worse prognosis on overall survival.

Kiba T, Ito T, Nakashima T, Okikawa Y, Kido M, Kimura A, Kameda K, Miyamae F, Tanaka S, Atsumi M, Sumitani Y, Shitakubo Y, Niimi H.

BMC Cancer. 2014 Jun 21;14:462. doi: 10.1186/1471-2407-14-462.

PMID:
24952705
[PubMed - in process]
Free PMC Article
18.

A novel proteasome inhibitor suppresses tumor growth via targeting both 19S proteasome deubiquitinases and 20S proteolytic peptidases.

Liu N, Liu C, Li X, Liao S, Song W, Yang C, Zhao C, Huang H, Guan L, Zhang P, Liu S, Hua X, Chen X, Zhou P, Lan X, Yi S, Wang S, Wang X, Dou QP, Liu J.

Sci Rep. 2014 Jun 10;4:5240. doi: 10.1038/srep05240.

PMID:
24912524
[PubMed - in process]
Free PMC Article
19.

Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group.

Ciombor KK, Feng Y, Benson AB 3rd, Su Y, Horton L, Short SP, Kauh JS, Staley C, Mulcahy M, Powell M, Amiri KI, Richmond A, Berlin J.

Invest New Drugs. 2014 Oct;32(5):1017-27. doi: 10.1007/s10637-014-0111-8. Epub 2014 Jun 4.

PMID:
24890858
[PubMed - in process]
Free PMC Article
20.

Molecularly targeted therapies in multiple myeloma.

de la Puente P, Muz B, Azab F, Luderer M, Azab AK.

Leuk Res Treatment. 2014;2014:976567. doi: 10.1155/2014/976567. Epub 2014 Apr 16. Review.

PMID:
24829804
[PubMed]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk